Drug Trial Radar · NCT06174766
A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
356
Actual
Start
May 10, 2024
Primary completion
Jan 8, 2026
Study completion Jan 8, 2026
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HGP2304 in patients with essential hypertension
Conditions
- Hypertension
Interventions
HGP2304-1Drug
Test drug
HGP2304-2Drug
Test drug
RLD2209-1Drug
Control drug
RLD2209-2Drug
Control drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 24 hours ambulatory systolic blood pressureTime frame: baseline, 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance hosptal
Seodaemun-gu, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.